160 related articles for article (PubMed ID: 9081370)
1. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.
Scambia G; De Vincenzo R; Ranelletti FO; Panici PB; Ferrandina G; D'Agostino G; Fattorossi A; Bombardelli E; Mancuso S
Eur J Cancer; 1996 May; 32A(5):877-82. PubMed ID: 9081370
[TBL] [Abstract][Full Text] [Related]
2. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin.
Giacomelli S; Gallo D; Apollonio P; Ferlini C; Distefano M; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Life Sci; 2002 Feb; 70(12):1447-59. PubMed ID: 11883719
[TBL] [Abstract][Full Text] [Related]
3. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.
Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S
Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth.
Scambia G; Ranelletti FO; Benedetti Panici P; Bonanno G; De Vincenzo R; Piantelli M; Mancuso S
Anticancer Drugs; 1990 Oct; 1(1):45-8. PubMed ID: 2131036
[TBL] [Abstract][Full Text] [Related]
5. Human ovarian cancer cell lines resistant to cisplatin, doxorubicin, and L-phenylalanine mustard are sensitive to delta 7-prostaglandin A1 and delta 12-prostaglandin J2.
Sasaki H; Takada K; Terashima Y; Ekimoto H; Takahashi K; Tsuruo T; Fukushima M
Gynecol Oncol; 1991 Apr; 41(1):36-40. PubMed ID: 2026357
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; De Vincenzo R; Bonanno G; Ferrandina G; Isola G; Mancuso S
Eur J Cancer; 1992; 28A(11):1885-9. PubMed ID: 1389532
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
8. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
9. Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction.
Ercoli A; Battaglia A; Raspaglio G; Fattorossi A; Alimonti A; Petrucci F; Caroli S; Mancuso S; Scambia G
Int J Cancer; 2000 Jan; 85(1):98-103. PubMed ID: 10585591
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.
Scambia G; Ranelletti FO; Panici PB; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Rumi C; Larocca LM; Mancuso S
Br J Cancer; 1990 Dec; 62(6):942-6. PubMed ID: 2257224
[TBL] [Abstract][Full Text] [Related]
11. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Pierelli L; Capelli A; Mancuso S
Cancer Chemother Pharmacol; 1991; 28(4):255-8. PubMed ID: 1879042
[TBL] [Abstract][Full Text] [Related]
12. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
14. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
15. Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression.
Catanzaro D; Gabbia D; Cocetta V; Biagi M; Ragazzi E; Montopoli M; Carrara M
Fitoterapia; 2018 Jan; 124():42-48. PubMed ID: 29031537
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
19. [Circumvention of cisplatin resistant ovarian cancer cells by antiestrogens].
Ishii K; Kita T; Kudo K; Hisano A; Hirata J; Imaizumi E; Tode T; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):19-26. PubMed ID: 7844449
[TBL] [Abstract][Full Text] [Related]
20. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
